Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PH009-1 in EGFR-mutated NSCLC
NCT06590194Phase 2Not yet recruiting
- Sponsor
- Suzhou Puhe Biopharma
- Start
- Sep 2024
- Primary completion
- Jun 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of PH009-1 in non-small cell lung cancer (NSCLC) (6 arms), sponsored by Suzhou Puhe Biopharma. Primary endpoints: Dose-Limiting Toxicities at 2 years, Treatment-Emergent Adverse Events at 2 years and 2 more. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
PH009-1
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06590194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06590194.